Evidence map›Paper›PMID 29702969›Full record

ArticleMedicine2018

Value of [18F]FDG-PET/CT and CA125, serum levels and kinetic parameters, in early detection of ovarian cancer recurrence: Influence of histological subtypes and tumor stages.

Azahara Palomar Muñoz, José Manuel Cordero García, Mª Del Prado Talavera Rubio, Ana Mª García Vicente, Francisco José Pena Pardo, Germán Andrés Jiménez Londoño, Ángel Soriano Castrejón, Enrique Aranda Aguilar

Registry-linked trialAbstract read
In one paragraph

Article in Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06533709 (Satisfactory Debulking Prediction Model for Advanced Ovarian Cancer Based on PET-CT Image Data and Its Clinical Application), which is not on this map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06533709 unknown statusnot on this mapstarted 2024, after this paper: background citation

Satisfactory Debulking Prediction Model for Advanced Ovarian Cancer Based on PET-CT Image Data and Its Clinical Application

TypeobservationalSponsorSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRan2024 to 2026Enrolled146ConditionsOvarian Cancer, Image, PredationArmsRadio-score
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Meta-analysis of the diagnostic value ofFrontiers in oncology · 2022
    Pooled it
  2. EANM guideline on the role of 2-[European journal of nuclear medicine and molecular imaging · 2021
    Guideline
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Azahara Palomar MuñozNuclear Medicine-PET IDI Department, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat (Barcelona).
José Manuel Cordero GarcíaNuclear Medicine Department, Hospital General Universitario de Ciudad Real, Ciudad Real.
Mª Del Prado Talavera RubioNuclear Medicine Department, Hospital General Universitario de Ciudad Real, Ciudad Real.
Ana Mª García VicenteNuclear Medicine Department, Hospital General Universitario de Ciudad Real, Ciudad Real.
Francisco José Pena PardoNuclear Medicine Department, Hospital General Universitario de Ciudad Real, Ciudad Real.
Germán Andrés Jiménez LondoñoNuclear Medicine Department, Hospital General Universitario de Ciudad Real, Ciudad Real.
Ángel Soriano CastrejónNuclear Medicine Department, Hospital General Universitario de Ciudad Real, Ciudad Real.
Enrique Aranda AguilarMedical Oncology Department, Hospital Universitario Reina Sofía, Córdoba, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To assess the diagnostic accuracy of CA125, its kinetic values and positron emission tomography/computed tomography with 2-deoxy-2-[F]fluoro-D-glucose ([F]FDG-PET/CT), in relation with tumor characteristics for suspected recurrence of ovarian cancer. To evaluate the performance of CA125-related parameters as a selection criteria to perform a [F]FDG-PET/CT.A retrospective analysis of 69 [F]FDG-PET/CT for suspected recurrence of ovarian cancer was performed. All patients had 2 measurements of CA125, before PET/CT, to calculate kinetic values, as CA125vel (CA125vel = [CA125a - CA125b]/time) and CA125dt (CA125dt = [log2 × time]/[logCA125a - CA125b]). Maximum standard uptake value (SUVmax) was calculated. The diagnostic accuracy was calculated for all the variables and the optimal cut-off value of each of them by the receiver-operating characteristics (ROC) analysis. All the tests were compared with tumor characteristics and clinical-radiological evolution during follow-up of at least 6 months.Fifty-five cases were diagnosed of recurrence (11 with CA125 <35 U/mL), while 14 showed no disease (11 with CA125 < 35 U/mL). All of them were correctly cataloged by PET/CT. CA125, CA125vel, and SUVmax showed higher levels in recurrent patients (mean 129.54 U/mL, 24.58 U/mL per mo, and 8.69 g/mL, respectively) than in nonrecurrent (mean 20.35 U/mL, 0.60 U/mL per mo, and 0.64 g/mL, respectively). No statistical differences in CA125dt were found. Patients with recurrence of high-grade serous carcinoma (HGSC) showed higher CA125 and CA125vel, without differences in the rest of subtypes and International Federation of Gynecology and Obstetrics stages. The ROC analyses for CA125, CA125vel, and CA125dt showed an area under the curve (AUC) of 0.873 (95% confidence interval [CI] 0.77-0.969), 0.903 (95% CI 0.813-0.994), and 0.727 (95% CI 0.542-0.913), respectively, with an optimal cut-off point of 23.95 U/mL, 4.49 U/mL per mo, and 3.36 months, respectively, while for the SUVmax the AUC was of 0.982 (95% CI 0.948-1.000), and the cut-off point of 2. Multivariate regression analysis identified CA125 and CA125vel as predictors of recurrence.[F]FDG-PET/CT is more accurate than the parameters obtained from the CA125 to detect early recurrence. CA125vel is the most suitable parameter, mainly in HGSC. Levels of CA125vel ≥ 4.49 U/mL per mo facilitate earlier detection by the execution of a [F]FDG-PET/CT. The calculation of these parameters is independent of tumor stage at diagnosis.

Indexed as

AgedBiomarkers, TumorCA-125 AntigenEarly Detection of CancerFemaleFluorodeoxyglucose F18HumansMiddle AgedNeoplasm Recurrence, LocalOvarian NeoplasmsPositron Emission Tomography Computed TomographyRetrospective StudiesROC CurveBiomarkers, TumorCA-125 AntigenFluorodeoxyglucose F18

Identifiers

PMID29702969
PMCPMC5944512

What OpenQuestion holds

Textmetadata
LicenceCC BY-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.